Harald Herholz

Learn More
BACKGROUND There has been an increase in 'risk sharing' schemes for pharmaceuticals between healthcare institutions and pharmaceutical companies in Europe in recent years as an additional approach to provide continued comprehensive and equitable healthcare. There is though confusion surrounding the terminology as well as concerns with existing schemes. (More)
INTRODUCTION European countries need to learn from each other to address unsustainable increases in pharmaceutical expenditures. OBJECTIVE To assess the influence of the many supply and demand-side initiatives introduced across Europe to enhance prescribing efficiency in ambulatory care. As a result provide future guidance to countries. METHODS Cross(More)
INTRODUCTION The appreciable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower generic prices and enhance their utilization. However, considerable variation in their use and prices. OBJECTIVE Assess the influence of multiple supply and demand-side initiatives across Europe for established medicines to enhance(More)
Seit 2004 haben alle Krankenkassen in Deutschland die Möglichkeit und seit 2007 die Verpflichtung, ihren Versicherten sowie deren Hausärzten die Teilnahme an einem Vertrag zur Hausarztzentrierten Versorgung (HZV) anzubieten. Ziel der HZV-Verträge ist es, die Rolle des Hausarztes als Koordinator im Gesundheitswesen zu stärken. Bisher ist jedoch wenig darüber(More)
If high sodium intake is involved in the pathogenesis of essential hypertension, the effects of changing the sodium intake should be demonstrable in the susceptible part of the normotensive population. Therefore, we have investigated the effects of moderate salt restriction in 52 young normotensive subjects with and without a family history of hypertension;(More)
AIM The aim of this article was to evaluate the influence of different demand-side measures to enhance the prescribing of generics in ambulatory care based on cross-national comparisons. METHODS An observational retrospective study was conducted using administrative databases from across Europe, documenting changes in reimbursed utilization and(More)
BACKGROUND There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed,(More)
In a double-blind cross-over study, 10 patients with stable angina pectoris owing to coronary heart disease were investigated in supine position during rest and bicycle exercise for the effect of 0.4 mg of intravenous (i.v.) isradipine in comparison to 2 mg i.v. nifedipine on cardiac hemodynamics and myocardial ischemia. At rest, both drugs significantly(More)
Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved.(More)
Mortality following myocardial infarction (MI) is greater among women than men and among Mexican Americans than non-Hispanic whites. Because therapy can affect mortality following MI, we examined differences in discharge therapy among these groups. Data regarding discharge therapy of 982 patients in the Corpus Christi Heart Project showed that women(More)